Silence Therapeutics (SLN) Depreciation & Amortization (CF) (2024 - 2026)

Silence Therapeutics has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $72000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $72000.0, down 1.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $311000.0 (up 9.12% YoY), and the FY2025 annual result was $312000.0, up 4.0% from the prior year.
• Depreciation & Amortization (CF) came in at $72000.0 for Q1 2026 at Silence Therapeutics, down from $77000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $88000.0 in Q1 2024 to a low of $40000.0 in Q4 2024.
• The 3-year median for Depreciation & Amortization (CF) is $81000.0 (2025), against an average of $76000.0.
• Peak annual rise in Depreciation & Amortization (CF) reached 92.5% in 2025, while the deepest fall reached 17.05% in 2025.
• Silence Therapeutics' Depreciation & Amortization (CF) stood at $40000.0 in 2024, then surged by 92.5% to $77000.0 in 2025, then dropped by 6.49% to $72000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $72000.0 (Q1 2026), $77000.0 (Q4 2025), and $81000.0 (Q3 2025), per Business Quant data.